Eli Lilly Expands Coverage for Obesity Medications
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Source: PRnewswire
- Expanded Coverage: Eli Lilly announced that its obesity medication portfolio will be covered by the three largest pharmacy benefit managers in the U.S., significantly increasing access to FDA-approved treatment options for millions of Americans, thereby enhancing patient choice and accessibility.
- Reduced Medication Costs: Starting June 1, eligible patients will pay as little as $25 per month for Foundayo and Zepbound, which is expected to significantly lower the financial burden on patients and promote broader adoption of these medications.
- Clinical Trial Validation: The ATTAIN-1 and ATTAIN-2 clinical trials enrolled over 4,500 individuals with obesity or overweight, demonstrating that Foundayo led to an average weight loss of 27.3 pounds (12.4%) over 72 weeks, providing robust evidence of its efficacy and further solidifying Lilly's market position in obesity treatment.
- Competitive Market Advantage: Zepbound, the most prescribed injectable obesity medication in the U.S., achieved an average weight loss of 15% (34 lbs) over 72 weeks, enhancing patients' quality of life and securing a larger market share for Lilly in the competitive obesity drug landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1082.920
Low
950.00
Averages
1192
High
1500
Current: 1082.920
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Expands Coverage for Obesity Medications
- Expanded Coverage: Eli Lilly announced that its obesity medication portfolio will be covered by the three largest pharmacy benefit managers in the U.S., significantly increasing access to FDA-approved treatment options for millions of Americans, thereby enhancing patient choice and accessibility.
- Reduced Medication Costs: Starting June 1, eligible patients will pay as little as $25 per month for Foundayo and Zepbound, which is expected to significantly lower the financial burden on patients and promote broader adoption of these medications.
- Clinical Trial Validation: The ATTAIN-1 and ATTAIN-2 clinical trials enrolled over 4,500 individuals with obesity or overweight, demonstrating that Foundayo led to an average weight loss of 27.3 pounds (12.4%) over 72 weeks, providing robust evidence of its efficacy and further solidifying Lilly's market position in obesity treatment.
- Competitive Market Advantage: Zepbound, the most prescribed injectable obesity medication in the U.S., achieved an average weight loss of 15% (34 lbs) over 72 weeks, enhancing patients' quality of life and securing a larger market share for Lilly in the competitive obesity drug landscape.
See More
CVS Restores Coverage for Eli Lilly's Weight Loss Drug
- Coverage Restoration: CVS Caremark will restore coverage for Eli Lilly's weight loss injection Zepbound as a preferred option starting October 1, significantly enhancing patient access and treatment options.
- New Drug Launch: Eli Lilly's newly approved obesity pill Foundayo will be available on plans from June 1, 2026, further enriching the company's portfolio in obesity treatment and strengthening its market competitiveness.
- Stock Milestone: Eli Lilly's shares hit an all-time high of $1,147.95 on Thursday, pushing its market capitalization to approximately $1.02 trillion, reflecting strong market demand for its obesity drugs and future growth potential.
- Competitive Landscape Shift: CVS's decision came after Eli Lilly agreed to lower drug prices, which will help Lilly compete more effectively with rival Novo Nordisk in the rapidly growing weight-loss market, enhancing its market share.
See More
Intense Pharmaceutical Rivalry: Novo Nordisk vs. Eli Lilly in GLP-1 Market
- Intensifying Market Competition: Novo Nordisk's Wegovy obesity drug grew 22% in Q1 2026, while Eli Lilly's Mounjaro and Zepbound saw increases of 125% and 80%, respectively, highlighting significant performance differences in the GLP-1 market, although Novo Nordisk is still in pursuit.
- Product Innovation Advantage: The launch of Novo Nordisk's oral Wegovy pill is attracting customers who prefer not to take injections, indicating its potential in the GLP-1 space, despite Eli Lilly's dominance in market share, underscoring the importance of product innovation in customer appeal.
- Valuation and Yield Appeal: Novo Nordisk boasts a dividend yield of 4.04%, significantly higher than Eli Lilly's 0.65%, with a P/E ratio around 10x, well below the industry average, making it attractive to dividend and value investors.
- Market Outlook: Although Novo Nordisk anticipates challenges in 2026, the strong early adoption of the Wegovy pill and its ability to attract new customers suggest that long-term volume will offset short-term price declines, showcasing its market potential.
See More
Competitive Analysis of Novo Nordisk and Eli Lilly
- Market Competition: In the GLP-1 weight loss drug market, Eli Lilly's sales of Mounjaro and Zepbound surged by 125% and 80% respectively, while Novo Nordisk's Wegovy business grew by 22% in Q1 2026, highlighting a significant disparity in market share between the two companies.
- Investment Attractiveness Comparison: While Eli Lilly's P/E ratio stands at 37x, significantly above the industry average of 24x, and its dividend yield is only 0.65%, Novo Nordisk offers a much more appealing P/E of around 10x and a dividend yield of 4%, making it more attractive to dividend investors.
- Product Innovation and Market Response: Novo Nordisk's newly launched Wegovy pill is perceived to be more effective than Eli Lilly's GLP-1 pill, attracting customers who prefer not to take injections, indicating its potential in the GLP-1 market despite facing challenges from price reductions in 2026.
- Investor Sentiment and Opportunity: Although Novo Nordisk is undervalued and investors are cautious about its future growth, the early strong performance of the Wegovy pill presents an opportunity for investors to enter at a lower price, particularly appealing to contrarian investors.
See More
Stocks Edge Up as Snowflake Surges 35% on Strong Earnings
- Market Dynamics: Stocks edged higher on Thursday following a 60-day ceasefire agreement between the U.S. and Iran, which initiated negotiations over Iran's nuclear program, while the personal consumption expenditures price index rose 0.4% month-over-month, slightly below the expected 0.5%, alleviating inflation concerns.
- Snowflake's Strong Performance: Data analytics firm Snowflake saw its shares surge 35% after a robust quarterly report, with CEO Sridhar Ramaswamy successfully pivoting the company towards an AI-focused business model, and a $6 billion commitment to Amazon further bolstered market confidence.
- Starbucks Recovery Signs: Starbucks is witnessing improved afternoon traffic, particularly between 3 p.m. and 5 p.m., which management identifies as crucial for enhancing profitability; Jim Cramer recommends buying Starbucks shares, projecting a target price of $120, indicating a potential upside of about 17%.
- Quick Market Recap: Stocks mentioned in Thursday's rapid-fire segment included CVS, Eli Lilly, and Marvell, with Jim Cramer's charitable trust holding positions in Amazon and Starbucks, providing trade alerts before executing trades.
See More
France Becomes First EU Nation to Reimburse Weight Loss Medications
- Reimbursement Policy: France's Health Minister Stephanie Rist announced that France is the first EU nation to reimburse weight loss medications, specifically for severely obese patients, marking a significant advancement in public health policy.
- Eligibility Criteria: Under the new policy, patients with a body mass index (BMI) of at least 35 with one comorbidity or a BMI of at least 40 will qualify for coverage, potentially benefiting around one million individuals in need.
- Financial Impact Assessment: The initiative is expected to cost approximately €100 million ($116 million) annually at full rollout, imposing a financial burden on French taxpayers while potentially reducing long-term healthcare costs associated with obesity.
- Market Competition Dynamics: With this policy, weight loss medications from Novo Nordisk (NVO) and Eli Lilly (LLY) will gain broader market acceptance in France, which may influence policy decisions in other EU countries and drive overall market growth.
See More
Eli Lilly Expands Coverage for Obesity Medications
- Expanded Coverage: Eli Lilly announced that its obesity medication portfolio will be covered by the three largest pharmacy benefit managers in the U.S., significantly increasing access to FDA-approved treatment options for millions of Americans, thereby enhancing patient choice and accessibility.
- Reduced Medication Costs: Starting June 1, eligible patients will pay as little as $25 per month for Foundayo and Zepbound, which is expected to significantly lower the financial burden on patients and promote broader adoption of these medications.
- Clinical Trial Validation: The ATTAIN-1 and ATTAIN-2 clinical trials enrolled over 4,500 individuals with obesity or overweight, demonstrating that Foundayo led to an average weight loss of 27.3 pounds (12.4%) over 72 weeks, providing robust evidence of its efficacy and further solidifying Lilly's market position in obesity treatment.
- Competitive Market Advantage: Zepbound, the most prescribed injectable obesity medication in the U.S., achieved an average weight loss of 15% (34 lbs) over 72 weeks, enhancing patients' quality of life and securing a larger market share for Lilly in the competitive obesity drug landscape.
See More
CVS Restores Coverage for Eli Lilly's Weight Loss Drug
- Coverage Restoration: CVS Caremark will restore coverage for Eli Lilly's weight loss injection Zepbound as a preferred option starting October 1, significantly enhancing patient access and treatment options.
- New Drug Launch: Eli Lilly's newly approved obesity pill Foundayo will be available on plans from June 1, 2026, further enriching the company's portfolio in obesity treatment and strengthening its market competitiveness.
- Stock Milestone: Eli Lilly's shares hit an all-time high of $1,147.95 on Thursday, pushing its market capitalization to approximately $1.02 trillion, reflecting strong market demand for its obesity drugs and future growth potential.
- Competitive Landscape Shift: CVS's decision came after Eli Lilly agreed to lower drug prices, which will help Lilly compete more effectively with rival Novo Nordisk in the rapidly growing weight-loss market, enhancing its market share.
See More
Intense Pharmaceutical Rivalry: Novo Nordisk vs. Eli Lilly in GLP-1 Market
- Intensifying Market Competition: Novo Nordisk's Wegovy obesity drug grew 22% in Q1 2026, while Eli Lilly's Mounjaro and Zepbound saw increases of 125% and 80%, respectively, highlighting significant performance differences in the GLP-1 market, although Novo Nordisk is still in pursuit.
- Product Innovation Advantage: The launch of Novo Nordisk's oral Wegovy pill is attracting customers who prefer not to take injections, indicating its potential in the GLP-1 space, despite Eli Lilly's dominance in market share, underscoring the importance of product innovation in customer appeal.
- Valuation and Yield Appeal: Novo Nordisk boasts a dividend yield of 4.04%, significantly higher than Eli Lilly's 0.65%, with a P/E ratio around 10x, well below the industry average, making it attractive to dividend and value investors.
- Market Outlook: Although Novo Nordisk anticipates challenges in 2026, the strong early adoption of the Wegovy pill and its ability to attract new customers suggest that long-term volume will offset short-term price declines, showcasing its market potential.
See More
Competitive Analysis of Novo Nordisk and Eli Lilly
- Market Competition: In the GLP-1 weight loss drug market, Eli Lilly's sales of Mounjaro and Zepbound surged by 125% and 80% respectively, while Novo Nordisk's Wegovy business grew by 22% in Q1 2026, highlighting a significant disparity in market share between the two companies.
- Investment Attractiveness Comparison: While Eli Lilly's P/E ratio stands at 37x, significantly above the industry average of 24x, and its dividend yield is only 0.65%, Novo Nordisk offers a much more appealing P/E of around 10x and a dividend yield of 4%, making it more attractive to dividend investors.
- Product Innovation and Market Response: Novo Nordisk's newly launched Wegovy pill is perceived to be more effective than Eli Lilly's GLP-1 pill, attracting customers who prefer not to take injections, indicating its potential in the GLP-1 market despite facing challenges from price reductions in 2026.
- Investor Sentiment and Opportunity: Although Novo Nordisk is undervalued and investors are cautious about its future growth, the early strong performance of the Wegovy pill presents an opportunity for investors to enter at a lower price, particularly appealing to contrarian investors.
See More
Stocks Edge Up as Snowflake Surges 35% on Strong Earnings
- Market Dynamics: Stocks edged higher on Thursday following a 60-day ceasefire agreement between the U.S. and Iran, which initiated negotiations over Iran's nuclear program, while the personal consumption expenditures price index rose 0.4% month-over-month, slightly below the expected 0.5%, alleviating inflation concerns.
- Snowflake's Strong Performance: Data analytics firm Snowflake saw its shares surge 35% after a robust quarterly report, with CEO Sridhar Ramaswamy successfully pivoting the company towards an AI-focused business model, and a $6 billion commitment to Amazon further bolstered market confidence.
- Starbucks Recovery Signs: Starbucks is witnessing improved afternoon traffic, particularly between 3 p.m. and 5 p.m., which management identifies as crucial for enhancing profitability; Jim Cramer recommends buying Starbucks shares, projecting a target price of $120, indicating a potential upside of about 17%.
- Quick Market Recap: Stocks mentioned in Thursday's rapid-fire segment included CVS, Eli Lilly, and Marvell, with Jim Cramer's charitable trust holding positions in Amazon and Starbucks, providing trade alerts before executing trades.
See More
France Becomes First EU Nation to Reimburse Weight Loss Medications
- Reimbursement Policy: France's Health Minister Stephanie Rist announced that France is the first EU nation to reimburse weight loss medications, specifically for severely obese patients, marking a significant advancement in public health policy.
- Eligibility Criteria: Under the new policy, patients with a body mass index (BMI) of at least 35 with one comorbidity or a BMI of at least 40 will qualify for coverage, potentially benefiting around one million individuals in need.
- Financial Impact Assessment: The initiative is expected to cost approximately €100 million ($116 million) annually at full rollout, imposing a financial burden on French taxpayers while potentially reducing long-term healthcare costs associated with obesity.
- Market Competition Dynamics: With this policy, weight loss medications from Novo Nordisk (NVO) and Eli Lilly (LLY) will gain broader market acceptance in France, which may influence policy decisions in other EU countries and drive overall market growth.
See More
